C970 Stock Chart & Stats
€5.16
€0.00(0.00%)
At close: 4:00 PM EDT
€5.16
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€5.16 - €36.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€7.24M
Enterprise Value€11.51
Total Cash (Recent Filing)€3.65M
Total Debt (Recent Filing)€1.80M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Nov 05, 2026EPS Estimate
-1.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-26.72
Shares Outstanding6,252,319
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.33
Price to Sales (P/S)10.83
P/FCF Ratio-0.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.45Price Target Upside-33.05% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-10.36
Revenue Forecast (FY)€471.11K
Bulls Say, Bears Say
Bulls Say
Regulatory And Clinical ProgressThe completed studies and FDA submission advance Co-Diagnostics toward commercialization of its respiratory multiplex assay. Regulatory and clinical validation can reduce adoption barriers and support broader use of the Co-Dx PCR platform.
International Platform And Manufacturing ExpansionInternational partnerships and localized production can expand distribution, lower logistical friction, and improve access to target markets. They also create a framework for scaling multiple assays rather than relying solely on U.S. demand.
Operating Expense ReductionsLower operating expenses and a narrower adjusted EBITDA loss show progress in controlling the cost base while regulatory and commercial programs continue. Sustained discipline could extend the runway and improve operating leverage if revenue scales.
Bears Say
Collapsed And Insufficient Revenue BaseThe sharp revenue contraction indicates that prior testing demand has not been replaced by recurring commercial sales. Very low revenue leaves fixed development and operating costs unsupported, making future performance highly dependent on successful product launches.
Persistent Cash Burn And Liquidity RiskSustained operating and free-cash-flow deficits are consuming the resources needed to fund regulatory, clinical, and commercial programs. The steep cash decline increases reliance on additional financing before meaningful revenue generation is established.
Eroded Equity Base And Financing DilutionThe shrinking equity cushion reflects accumulated losses and reduces financial flexibility. Recent warrant financing provides liquidity but expands potential dilution, while the company continues evaluating equity, debt, and strategic funding alternatives.
Co-Diagnostics News
C970 FAQ
What was Co-Diagnostics Inc’s price range in the past 12 months?
Co-Diagnostics Inc lowest stock price was €5.16 and its highest was €36.00 in the past 12 months.
What is Co-Diagnostics Inc’s market cap?
Co-Diagnostics Inc’s market cap is €7.24M.
When is Co-Diagnostics Inc’s upcoming earnings report date?
Co-Diagnostics Inc’s upcoming earnings report date is Nov 05, 2026 which is in 77 days.
How were Co-Diagnostics Inc’s earnings last quarter?
Co-Diagnostics Inc released its earnings results on Aug 13, 2026. The company reported -€1.261 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Co-Diagnostics Inc overvalued?
According to Wall Street analysts Co-Diagnostics Inc’s price is currently Overvalued.
Does Co-Diagnostics Inc pay dividends?
Co-Diagnostics Inc does not currently pay dividends.
What is Co-Diagnostics Inc’s EPS estimate?
Co-Diagnostics Inc’s EPS estimate is -1.08.
How many shares outstanding does Co-Diagnostics Inc have?
Co-Diagnostics Inc has 6,252,319 shares outstanding.
What happened to Co-Diagnostics Inc’s price movement after its last earnings report?
Co-Diagnostics Inc reported an EPS of -€1.261 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Co-Diagnostics Inc?
Currently, no hedge funds are holding shares in DE:C970
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Co-Diagnostics Inc
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
C970 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed meaningful operational and regulatory progress — including a dual FDA submission for an upper respiratory multiplex assay, >1,400-patient clinical enrollment, >10,000 analytical PCR runs, TB program advancement toward ERPD, a blood-based Ebola proof-of-concept, strengthened international manufacturing partnerships, and reduced operating expenses that improved net loss and adjusted EBITDA. However, these positives are counterbalanced by a very low revenue base ($166K), a steep decline in cash to $3.6M (≈70% drop), continued operating losses, and materially reduced total assets. While execution milestones materially de-risk the technology and regulatory path, the company faces near-term liquidity and commercialization scaling risks.View all DE:C970 earnings summariesC970 Stock 12 Month Forecast
Average Price Target
€3.45
▼(-33.05% Downside)
Sintx Technologies
―
Vivos Therapeutics
―
Adagio Medical Holdings
―
―
Heart Test Laboratories, Inc.
―